Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 271
Filtrer
1.
Int J Mol Sci ; 25(15)2024 Aug 05.
Article de Anglais | MEDLINE | ID: mdl-39126117

RÉSUMÉ

Avian influenza virus has been long considered the main threat for a future pandemic. Among the possible avian influenza virus subtypes, A(H5N1) clade 2.3.4.4b is becoming enzootic in mammals, representing an alarming step towards a pandemic. In particular, genotype B3.13 has recently caused an outbreak in US dairy cattle. Since pandemic preparedness is largely based on the availability of prepandemic candidate vaccine viruses, in this review we will summarize the current status of the enzootics, and challenges for H5 vaccine manufacturing and delivery.


Sujet(s)
Sous-type H5N1 du virus de la grippe A , Vaccins antigrippaux , Grippe chez les oiseaux , Animaux , Vaccins antigrippaux/immunologie , Humains , Sous-type H5N1 du virus de la grippe A/immunologie , Sous-type H5N1 du virus de la grippe A/génétique , Grippe chez les oiseaux/prévention et contrôle , Grippe chez les oiseaux/virologie , Grippe chez les oiseaux/épidémiologie , Grippe humaine/prévention et contrôle , Grippe humaine/épidémiologie , Grippe humaine/immunologie , Grippe humaine/virologie , Oiseaux/virologie , Pandémies/prévention et contrôle
3.
Emerg Infect Dis ; 30(9)2024 Aug 10.
Article de Anglais | MEDLINE | ID: mdl-39127126

RÉSUMÉ

The 2022 global mpox outbreak was driven by human-to-human transmission, but modes of transmission by sexual relationship versus sexual contact remain unclear. We evaluated sexual transmission of mpox by using monkeypox virus (MPXV) G2R-mRNA as a marker of ongoing viral replication through in vitro experiments. We analyzed clinical samples of 15 MPXV-positive patients in Italy from different biological regions by using the setup method. The presence of MPXV DNA, MPXV G2R-mRNA, or both in all analyzed lesion swab samples, independent of viral load, confirmed a higher infectivity risk from skin lesions. Positivity for MPXV G2R-mRNA in nasopharyngeal swabs was associated with high MPXV load, whereas positive results for MPXV G2R-mRNA were obtained only in the 2 semen samples with the lowest MPXV loads. Our results suggest that close or skin-to-skin contact during sexual intercourse is the main route of sexual transmission and that semen is a minor driver of infection, regardless of MPXV load.

4.
Viruses ; 16(7)2024 Jun 24.
Article de Anglais | MEDLINE | ID: mdl-39066176

RÉSUMÉ

Enteroviruses (EVs) are ubiquitous viruses that circulate worldwide, causing sporadic or epidemic infections, typically during the summer and fall. They cause a broad spectrum of illnesses, ranging from an unspecified febrile clinical presentation to a severe illness. EVs are recognized to be the most frequent etiological agents of aseptic meningitis in children. However, as the infection is usually mild and self-limiting, it remains underestimated, and the epidemiology of EVs is poorly understood. To date, no vaccine or effective therapy for all types of enteroviruses is available, and EVs constitute a public health concern. Here, we investigated the molecular epidemiology of EV strains circulating in the Lazio region over a 10-year time span (2012-2023) by using a sequence-typing approach and phylogenetic analysis. The epidemiological trend of EV infection has undergone changes during the SARS-CoV-2 pandemic (2020-2021), which resulted in a modification in terms of the number of diagnosed cases and seasonality. From 2022, the circulation of EVs showed a behavior typical of the pre-pandemic period, although changes in predominantly circulating strains have been noted. Both epidemic and sporadic circulation events have been characterized in the Lazio region. Further analyses are needed to better characterize any strain with higher potential pathogenic power and to identify possible recombinant strains.


Sujet(s)
Infections à entérovirus , Enterovirus , Génotype , Épidémiologie moléculaire , Phylogenèse , Humains , Infections à entérovirus/virologie , Infections à entérovirus/épidémiologie , Enterovirus/génétique , Enterovirus/classification , Enterovirus/isolement et purification , Saisons , COVID-19/épidémiologie , COVID-19/virologie , SARS-CoV-2/génétique , SARS-CoV-2/classification , Enfant
5.
Viruses ; 16(7)2024 Jun 27.
Article de Anglais | MEDLINE | ID: mdl-39066203

RÉSUMÉ

Despite emerging evidence indicating that molecular SARS-CoV-2 tests performed on saliva have diagnostic sensitivity and specificity comparable to those observed with nasopharyngeal swabs (NPSs), most in vivo follow-up studies on the efficacy of drugs against SARS-CoV-2 have been performed on NPSs, not considering saliva as a possible alternative matrix. For this reason, in this study, we used, in parallel, saliva and NPS samples for the detection of SARS-CoV-2 by real-time RT-PCR in patients receiving Tixagevimab/Cilgavimab, Nirmatrelvir/Ritonavir, or Sotrovimab as a treatment against SARS-CoV-2. Our results showed a good correlation between the NPS and saliva samples for each drug; moreover, comparable changes in the cycle threshold (Ct) levels in saliva and NPSs were observed both 7 days and 30 days after treatment, thus confirming that the saliva represents a good matrix for in vivo follow-up studies verifying the effectiveness of treatments against SARS-CoV-2.


Sujet(s)
Traitements médicamenteux de la COVID-19 , COVID-19 , Partie nasale du pharynx , Ritonavir , SARS-CoV-2 , Salive , Sensibilité et spécificité , Humains , Salive/virologie , SARS-CoV-2/isolement et purification , SARS-CoV-2/effets des médicaments et des substances chimiques , SARS-CoV-2/génétique , COVID-19/diagnostic , COVID-19/virologie , Ritonavir/usage thérapeutique , Partie nasale du pharynx/virologie , Études de suivi , Antiviraux/usage thérapeutique , Résultat thérapeutique , Anticorps monoclonaux humanisés/usage thérapeutique , Association médicamenteuse , Lopinavir/usage thérapeutique , Femelle , Mâle , Détection de l'acide nucléique du virus de la COVID-19/méthodes , Adulte d'âge moyen
6.
Vaccines (Basel) ; 12(7)2024 Jul 17.
Article de Anglais | MEDLINE | ID: mdl-39066422

RÉSUMÉ

Objective. We aimed to report the real-world use and outcomes over time in immunocompromised individuals receiving tixagevimab/cilgavimab (T/C) pre-exposure prophylaxis (PrEP). Methods. This observational study included participants who received T/C PrEP, categorized into three groups: (i) No COVID-19 (NoC), i.e., participants who never had COVID-19; (ii) Hybrids (H), i.e., participants who had COVID-19 before PrEP; and (iii) Break-through Infections (BTIs), i.e., participants who had COVID-19 after PrEP. The study measured several immune markers at the administration of T/C (T0) at 3 (T1), 6 (T2), and 9 (T3) months afterward. These markers included: anti-receptor-binding domain (RBD) IgG antibodies; BA.5-neutralizing antibodies (nAbs); mucosal IgG; and T cell immunity. The incidence rate ratios for BTIs were analyzed using a Poisson regression model. Results. A total of 231 participants with a median age of 63 years (IQR 54.0-73.0). were included. Among these, 84% had hematological diseases and received a median of three vaccine doses. N = 72 participants belonged to the NoC group, N = 103 to the H group, and n = 56 to the BTI group (24%), with most BTIs being mild/moderate. The incidence rate (IR) of BTIs was 4.2 per 100 patient-months (95% CI 3.2-5.4), with no associated risk factors identified. There was a significant increase in anti-RBD IgG levels 3 months after the T/C administration in all groups, followed by a decline at 6 months, whereas at the same time points, geometric mean titers (GMTs) of anti-BA.5 nAbs were low for all groups and were around or below the detection threshold. No significant changes were observed in IFN-γ levels. The mucosal immune response was observed only 3 months after the PrEP administration. Conclusion. We provided a real-world experience model on the clinical efficacy of T/C PrEP in preventing severe COVID-19 during the Omicron wave through a comprehensive virological and immunological study. While waiting for the arrival of new monoclonal antibodies that can effectively neutralize the most recent variants, T/C PrEP remains the only viable strategy in the available armamentarium today to prevent COVID-19 complications in an extremely fragile population with suboptimal immune responses to COVID-19 vaccines.

7.
Int J Mol Sci ; 25(14)2024 Jul 15.
Article de Anglais | MEDLINE | ID: mdl-39062987

RÉSUMÉ

Torque Teno Virus (TTV) is a ubiquitous component of the human virome, not associated with any disease. As its load increases when the immune system is compromised, such as in kidney transplant (KT) recipients, TTV load monitoring has been proposed as a method to assess immunosuppression. In this prospective study, TTV load was measured in plasma and urine samples from 42 KT recipients, immediately before KT and in the first 150 days after it. Data obtained suggest that TTV could be a relevant marker for evaluating immune status and could be used as a guide to predict the onset of infectious complications in the follow-up of KT recipients. Since we observed no differences considering distance from transplantation, while we found a changing trend in days before viral infections, we suggest to consider changes over time in the same subjects, irrespective of time distance from transplantation.


Sujet(s)
Marqueurs biologiques , Transplantation rénale , Virus torque teno , Charge virale , Transplantation rénale/effets indésirables , Humains , Marqueurs biologiques/urine , Marqueurs biologiques/sang , Mâle , Adulte d'âge moyen , Femelle , Adulte , Infections à virus à ADN/urine , Infections à virus à ADN/sang , Infections à virus à ADN/virologie , Études prospectives , Receveurs de transplantation , Sujet âgé
8.
J Infect Chemother ; 2024 Jul 21.
Article de Anglais | MEDLINE | ID: mdl-39043318

RÉSUMÉ

Human adenoviruses are the causative agents of 5-7% of viral respiratory infections, mainly caused by species B and C. They can infect all age groups, but children are usually at high risk of infections. Adenovirus epidemiology is well documented in East-Asian countries but little is known about adenovirus circulation in Europe in recent years. This multicentre retrospective study aimed to investigate the circulation and molecular epidemiology of hAdVs. This surveillance collected a total of 54463 respiratory specimens between January 1, 2022 and June 20, 2023 were tested for the presence of respiratory viruses. Our results showed that adenovirus was detected in 6.6 % of all cases of acute respiratory infection included in the study and the median age of positive patients was 3 years, with male children in 1-2 years age group being the most affected. 43.5 % of adenovirus cases were co-infected with at least one other respiratory virus, and rhinovirus was co-detected in 54 % of cases. Genotyping of adenovirus allowed the identification of 6 different genotypes circulating in Italy, among which type B3 was the most frequently detected.

9.
Article de Anglais | MEDLINE | ID: mdl-39028674

RÉSUMÉ

BACKGROUND: Transmitted drug resistance (TDR) is still a critical aspect for the management of individuals living with HIV-1. Thus, its evaluation is crucial to optimize HIV care. METHODS: Overall, 2386 HIV-1 protease/reverse transcriptase and 1831 integrase sequences from drug-naïve individuals diagnosed in north and central Italy between 2015 and 2021 were analysed. TDR was evaluated over time. Phylogeny was generated by maximum likelihood. Factors associated with TDR were evaluated by logistic regression. RESULTS: Individuals were mainly male (79.1%) and Italian (56.2%), with a median (IQR) age of 38 (30-48). Non-B infected individuals accounted for 44.6% (N = 1065) of the overall population and increased over time (2015-2021, from 42.1% to 51.0%, P = 0.002). TDR prevalence to any class was 8.0% (B subtype 9.5% versus non-B subtypes 6.1%, P = 0.002) and remained almost constant over time. Overall, 300 transmission clusters (TCs) involving 1155 (48.4%) individuals were identified, with a similar proportion in B and non-infected individuals (49.7% versus 46.8%, P = 0.148). A similar prevalence of TDR among individuals in TCs and those out of TCs was found (8.2% versus 7.8%, P = 0.707).By multivariable analysis, subtypes A, F, and CFR02_AG were negatively associated with TDR. No other factors, including being part of TCs, were significantly associated with TDR. CONCLUSIONS: Between 2015 and 2021, TDR prevalence in Italy was 8% and remained almost stable over time. Resistant strains were found circulating regardless of being in TCs, but less likely in non-B subtypes. These results highlight the importance of a continuous surveillance of newly diagnosed individuals for evidence of TDR to inform clinical practice.

10.
Sci Rep ; 14(1): 13487, 2024 06 12.
Article de Anglais | MEDLINE | ID: mdl-38866796

RÉSUMÉ

Since spring 2022, the global epidemiology of the monkeypox virus (MPXV) has changed. The unprecedented increase of human clade II MPXV cases worldwide heightened concerns about this emerging zoonotic disease. We analysed the positivity rates, viral loads, infectiousness, and persistence of MPXV DNA for up to 4 months in several biological samples from 89 MPXV-confirmed cases. Our data showed that viral loads and positivity rates were higher during the first two weeks of symptoms for all sample types. Amongst no-skin-samples, respiratory specimens showed higher MPXV DNA levels and median time until viral clearance, suggesting their usefulness in supporting MPXV diagnosis, investigating asymptomatic patients, and monitoring viral shedding. Infectious virus was cultured from respiratory samples, semen, and stools, with high viral loads and collected within the first 10 days. Notably, only one saliva and one semen were found positive for viral DNA after 71 and 31 days from symptoms, respectively. The focus on bloodstream samples showed the best testing sensitivity in plasma, reporting the overall highest MPXV DNA detection rate and viral loads during the 3-week follow-up as compared to serum and whole-blood. The data here presented can be useful for MPXV diagnostics and a better understanding of the potential alternative routes of its onward transmission.


Sujet(s)
Liquides biologiques , ADN viral , Virus de la variole simienne , Charge virale , Humains , ADN viral/génétique , Liquides biologiques/virologie , Mâle , Virus de la variole simienne/génétique , Virus de la variole simienne/isolement et purification , Cinétique , Sperme/virologie , Orthopoxvirose simienne/virologie , Orthopoxvirose simienne/épidémiologie , Orthopoxvirose simienne/diagnostic , Salive/virologie , Femelle , Adulte , Excrétion virale , Adulte d'âge moyen
11.
Viruses ; 16(6)2024 Jun 15.
Article de Anglais | MEDLINE | ID: mdl-38932255

RÉSUMÉ

Quantification of Torquetenovirus (TTV) viremia is becoming important for evaluating the status of the immune system in solid organ transplant recipients, monitoring the appearance of post-transplant complications, and controlling the efficacy of maintenance immunosuppressive therapy. Thus, diagnostic approaches able to scale up TTV quantification are needed. Here, we report on the development and validation of a real-time PCR assay for TTV quantification on the Hologic Panther Fusion® System by utilizing its open-access channel. The manual real-time PCR previously developed in our laboratories was optimized to detect TTV DNA on the Hologic Panther Fusion® System. The assay was validated using clinical samples. The automated TTV assay has a limit of detection of 1.6 log copies per ml of serum. Using 112 samples previously tested via manual real-time PCR, the concordance in TTV detection was 93% between the assays. When the TTV levels were compared, the overall agreement between the methods, as assessed using Passing-Bablok linear regression and Bland-Altman analyses, was excellent. In summary, we validated a highly sensitive and accurate method for the diagnostic use of TTV quantification on a fully automated Hologic Panther Fusion® System. This will greatly improve the turnaround time for TTV testing and better support the laboratory diagnosis of this new viral biomarker.


Sujet(s)
Infections à virus à ADN , Réaction de polymérisation en chaine en temps réel , Charge virale , Virémie , Réaction de polymérisation en chaine en temps réel/méthodes , Virémie/diagnostic , Virémie/virologie , Humains , Charge virale/méthodes , Infections à virus à ADN/diagnostic , Infections à virus à ADN/virologie , Sensibilité et spécificité , Virus torque teno/génétique , Virus torque teno/isolement et purification , ADN viral/génétique , ADN viral/sang , Limite de détection , Reproductibilité des résultats , Laboratoire automatique/méthodes
12.
Viruses ; 16(6)2024 Jun 20.
Article de Anglais | MEDLINE | ID: mdl-38932281

RÉSUMÉ

The blood virome is dominated by the Anelloviridae family, which emerges early in life; the anellome, which represents the variety of anelloviruses within an individual, stabilizes by adulthood [...].


Sujet(s)
Anellovirus , Virome , Humains , Anellovirus/génétique , Anellovirus/isolement et purification , Anellovirus/classification , Génome viral
13.
Int J Mol Sci ; 25(11)2024 May 27.
Article de Anglais | MEDLINE | ID: mdl-38892022

RÉSUMÉ

Cigarette smoking is a primary contributor to mortality risks and is associated with various diseases. Among these, COPD represents a significant contributor to global mortality and disability. The objective of this study is to investigate the effect of smoking on a selected battery of variables, with an emphasis on DNA damage. A total of 87 elderly patients diagnosed with COPD, divided into three groups based on their smoking history (current, former, never-smokers), were evaluated using a cross-sectional approach. Clinical features including mortality and inflammatory/oxidative parameters (Lymphocytes/Monocytes, Neutrophils/Lymphocytes, Platelets/Lymphocytes ratio), SII, MDA, 8-Oxo-dG, and IL6 (ELISA assay), as well as DNA damage (comet assay), were investigated. Virus infection, i.e., influenza A virus subtype H1N1, JC polyomavirus (JCPyV), BK polyomavirus (BKPyV), and Torquetenovirus (TTV), was also tested. Current smokers exhibit higher levels of comorbidity (CIRS; p < 0.001), Platelets/Lymphocytes ratio (p < 0.001), systemic immune inflammation (p < 0.05), and DNA damage (p < 0.001). Former smokers also showed higher values for parameters associated with oxidative damage and showed a much lower probability of surviving over 5 years compared to never- and current smokers (p < 0.0017). This study showed a clear interaction between events which are relevant to the oxidative pathway and cigarette smoking. A category of particular interest is represented by former smokers, especially for lower survival, possibly due to the presence of more health problems. Our findings raise also the attention to other parameters which are significantly affected by smoking and are useful to monitor COPD patients starting a program of pulmonary rehabilitation (DNA damage, inflammation parameters, and selected viral infections).


Sujet(s)
Fumer des cigarettes , Altération de l'ADN , Stress oxydatif , Broncho-pneumopathie chronique obstructive , Humains , Mâle , Femelle , Sujet âgé , Fumer des cigarettes/effets indésirables , Études transversales , Adulte d'âge moyen , Marqueurs biologiques , Inflammation
14.
Int J Mol Sci ; 25(11)2024 Jun 03.
Article de Anglais | MEDLINE | ID: mdl-38892344

RÉSUMÉ

SARS-CoV-2 is a highly infectious virus responsible for the COVID-19 pandemic. Therefore, it is important to assess the risk of SARS-CoV-2 infection, especially in persistently positive patients. Rapid discrimination between infectious and non-infectious viruses aids in determining whether prevention, control, and treatment measures are necessary. For this purpose, a method was developed and utilized involving a pre-treatment with 50 µM of propidium monoazide (PMAxx, a DNA intercalant) combined with a digital droplet PCR (ddPCR). The ddPCR method was performed on 40 nasopharyngeal swabs (NPSs) both before and after treatment with PMAxx, revealing a reduction in the viral load at a mean of 0.9 Log copies/mL (SD ± 0.6 Log copies/mL). Furthermore, six samples were stratified based on the Ct values of SARS-CoV-2 RNA (Ct < 20, 20 < Ct < 30, Ct > 30) and analyzed to compare the results obtained via a ddPCR with viral isolation and a negative-chain PCR. Of the five samples found positive via a ddPCR after the PMAxx treatment, two of the samples showed the highest post-treatment SARS-CoV-2 loads. The virus was isolated in vitro from both samples and the negative strand chains were detected. In three NPS samples, SARS CoV-2 was present post-treatment at a low level; it was not isolated in vitro, and, when detected, the strand was negative. Our results indicate that the established method is useful for determining whether the SARS-CoV-2 within positive NPS samples is intact and capable of causing infection.


Sujet(s)
Azotures , COVID-19 , Partie nasale du pharynx , Propidium , SARS-CoV-2 , Charge virale , Humains , SARS-CoV-2/génétique , SARS-CoV-2/isolement et purification , Azotures/composition chimique , Propidium/analogues et dérivés , Propidium/composition chimique , COVID-19/virologie , Charge virale/méthodes , Partie nasale du pharynx/virologie , ARN viral/génétique , ARN viral/isolement et purification , Détection de l'acide nucléique du virus de la COVID-19/méthodes , Réaction de polymérisation en chaîne/méthodes
16.
Clin Microbiol Rev ; 37(2): e0011923, 2024 Jun 13.
Article de Anglais | MEDLINE | ID: mdl-38771027

RÉSUMÉ

SUMMARYSince the emergence of COVID-19 in 2020, an unprecedented range of therapeutic options has been studied and deployed. Healthcare providers have multiple treatment approaches to choose from, but efficacy of those approaches often remains controversial or compromised by viral evolution. Uncertainties still persist regarding the best therapies for high-risk patients, and the drug pipeline is suffering fatigue and shortage of funding. In this article, we review the antiviral activity, mechanism of action, pharmacokinetics, and safety of COVID-19 antiviral therapies. Additionally, we summarize the evidence from randomized controlled trials on efficacy and safety of the various COVID-19 antivirals and discuss unmet needs which should be addressed.


Sujet(s)
Antiviraux , Traitements médicamenteux de la COVID-19 , COVID-19 , SARS-CoV-2 , Humains , Antiviraux/usage thérapeutique , SARS-CoV-2/effets des médicaments et des substances chimiques , COVID-19/thérapie
17.
Future Microbiol ; 19(9): 761-769, 2024 Jun 12.
Article de Anglais | MEDLINE | ID: mdl-38700284

RÉSUMÉ

Aim: Wastewater-based epidemiology (WBE) is increasingly used to monitor pandemics. In this manuscript, we review methods and limitations of WBE, as well as their online dashboards. Materials & methods: Online dashboards were retrieved using PubMed and search engines, and annotated for timeliness, availability of English version, details on SARS-CoV-2 sublineages, normalization by population and PPMoV load, availability of case/hospitalization count charts and of raw data for export. Results: We retrieved 51 web portals, half of them from Europe. Africa is represented from South Africa only, and only seven portals are available from Asia. Conclusion: WBS provides near-real-time cost-effective monitoring of analytes across space and time in populations. However, tremendous heterogeneity still persists in the SARS-CoV-2 WBE literature.


Monitoring the amount of a virus in the sewage system provides a way to work out the circulation of the virus among a population at a given time. Standard procedures are needed to produce data that can be compared across countries. Timely sharing of wastewater surveillance data across publicly accessible web portals is important to inform researchers and plan public health policies. This study shows that we are still far away from standardization and timely and transparent reporting.


Sujet(s)
COVID-19 , SARS-CoV-2 , Eaux usées , Humains , COVID-19/épidémiologie , COVID-19/diagnostic , SARS-CoV-2/isolement et purification , Eaux usées/virologie , Surveillance épidémiologique fondée sur les eaux usées , Pandémies , Asie/épidémiologie , Europe/épidémiologie , Internet
18.
Heliyon ; 10(9): e29842, 2024 May 15.
Article de Anglais | MEDLINE | ID: mdl-38699019

RÉSUMÉ

In a restricted subset of people living with HIV-1 (PLWH) on antiretroviral therapy (ART) with persistent suppressed viral load (i.e., pol-based HIV-RNA repeatedly undetected), a dual-target (pol and LTR) diagnostic assay for HIV-RNA monitoring can measure quantifiable levels of viral loads (VL) above 30 copies/mL exclusively through the amplification of the LTR region, while the pol target results undetected. We report a patient who shows high levels of HIV-RNA detected exclusively through amplification of the LTR region while undetected by the pol region, during a long monitoring period, from 2018 to date. In this follow-up, the ART was modified without reaching LTR-based undetected HIV-RNA values. Immunological and virological parameters remained optimal with a progressive and steady gain of the CD4/CD8 ratio. The clinical history of this patient, shows that LTR-based viremia above 50 copies/mL can be found occasionally or persistently in the plasma of PLWH under suppressive ART, even at high levels. Based on previous studies, VL detected and quantified exclusively through the amplification of the LTR region corresponds to partial or incomplete HIV-RNA transcripts, which cannot trigger new infections. Interestingly, changes in ART do not eliminate repeated findings of these unusual viral elements.

19.
J Med Virol ; 96(5): e29642, 2024 May.
Article de Anglais | MEDLINE | ID: mdl-38708812

RÉSUMÉ

Molnupiravir, an oral direct-acting antiviral effective in vitro against SARS-CoV-2, has been largely employed during the COVID-19 pandemic, since December 2021. After marketing and widespread usage, a progressive increase in SARS-CoV-2 lineages characterized by a higher transition/transversion ratio, a characteristic signature of molnupiravir action, appeared in the Global Initiative on Sharing All Influenza Data (GISAID) and International Nucleotide Sequence Database Collaboration (INSDC) databases. Here, we assessed the drug effects by SARS-CoV-2 whole-genome sequencing on 38 molnupiravir-treated persistently positive COVID-19 outpatients tested before and after treatment. Seventeen tixagevimab/cilgavimab-treated outpatients served as controls. Mutational analyses confirmed that SARS-CoV-2 exhibits an increased transition/transversion ratio seven days after initiation of molnupiravir. Moreover we observed an increased G->A ratio compared to controls, which was not related to apolipoprotein B mRNAediting enzyme, catalytic polypeptide-like (APOBEC) activity. In addition, we demonstrated for the first time an increased diversity and complexity of the viral quasispecies.


Sujet(s)
Antiviraux , Traitements médicamenteux de la COVID-19 , Cytidine/analogues et dérivés , Génome viral , Hydroxylamines , SARS-CoV-2 , Humains , SARS-CoV-2/génétique , SARS-CoV-2/effets des médicaments et des substances chimiques , Antiviraux/usage thérapeutique , Antiviraux/pharmacologie , Hydroxylamines/pharmacologie , Hydroxylamines/usage thérapeutique , Mâle , Femelle , Études cas-témoins , Adulte d'âge moyen , Cytidine/usage thérapeutique , Cytidine/pharmacologie , Sujet âgé , Adulte , Séquençage du génome entier , Variation génétique , Uridine/pharmacologie , COVID-19/virologie , Mutation
20.
J Neurol ; 271(7): 4310-4325, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-38644373

RÉSUMÉ

Amyotrophic lateral sclerosis (ALS) is an untreatable and clinically heterogeneous condition primarily affecting motor neurons. The ongoing quest for reliable biomarkers that mirror the disease status and progression has led to investigations that extend beyond motor neurons' pathology, encompassing broader systemic factors such as metabolism, immunity, and the microbiome. Our study contributes to this effort by examining the potential role of microbiome-related components, including viral elements, such as torque tenovirus (TTV), and various inflammatory factors, in ALS. In our analysis of serum samples from 100 ALS patients and 34 healthy controls (HC), we evaluated 14 cytokines, TTV DNA load, and 18 free fatty acids (FFA). We found that the evaluated variables are effective in differentiating ALS patients from healthy controls. In addition, our research identifies four unique patient clusters, each characterized by distinct biological profiles. Intriguingly, no correlations were found with site of onset, sex, progression rate, phenotype, or C9ORF72 expansion. A remarkable aspect of our findings is the discovery of a gender-specific relationship between levels of 2-ethylhexanoic acid and patient survival. In addition to contributing to the growing body of evidence suggesting altered peripheral immune responses in ALS, our exploratory research underscores metabolic diversity challenging conventional clinical classifications. If our exploratory findings are validated by further research, they could significantly impact disease understanding and patient care customization. Identifying groups based on biological profiles might aid in clustering patients with varying responses to treatments.


Sujet(s)
Sclérose latérale amyotrophique , Inflammation , Virome , Humains , Sclérose latérale amyotrophique/sang , Sclérose latérale amyotrophique/immunologie , Mâle , Femelle , Adulte d'âge moyen , Sujet âgé , Inflammation/sang , Cytokines/sang , Virus torque teno/génétique , Acide gras libre/sang , Adulte , Marqueurs biologiques/sang , ADN viral/sang
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE